119 related articles for article (PubMed ID: 8548750)
1. Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.
Amoroso AR; Clark JI; Litwin S; Hsieh-Ma S; Shi T; Alpaugh RK; Adams GP; Wolf EJ; Ring DB; Weiner LM
Cancer Res; 1996 Jan; 56(1):113-20. PubMed ID: 8548750
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
3. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
4. Murine bispecific antibody 1A10 directed to human transferrin receptor and a 42-kDa tumor-associated glycoprotein.
Shi T; Hsieh-Ma ST; Reeder J; Ring DB
Clin Immunol Immunopathol; 1996 Feb; 78(2):188-95. PubMed ID: 8625561
[TBL] [Abstract][Full Text] [Related]
5. In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine.
Hsieh-Ma ST; Shi T; Reeder J; Ring DB
Clin Immunol Immunopathol; 1996 Aug; 80(2):185-93. PubMed ID: 8764564
[TBL] [Abstract][Full Text] [Related]
6. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
7. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects.
White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS
Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993
[TBL] [Abstract][Full Text] [Related]
8. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia.
Sauvage CA; Mendelsohn JC; Lesley JF; Trowbridge IS
Cancer Res; 1987 Feb; 47(3):747-53. PubMed ID: 3802079
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC; Jiang XP; Elliott RL; Head JF
Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
12. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
[TBL] [Abstract][Full Text] [Related]
13. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
[TBL] [Abstract][Full Text] [Related]
14. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
16. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
19. Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts.
Salcedo R; Martins-Green M; Gertz B; Oppenheim JJ; Murphy WJ
Clin Cancer Res; 2002 Aug; 8(8):2655-65. PubMed ID: 12171898
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]